EATRIS-Plus project funded by the European Commission
EATRIS Norway is pleased to announce that the ‘EATRIS-Plus’ proposal has been funded by the European Commission under the INFRADEV-3 call, which concerns the development and long sustainability of new pan-European research infrastructures.
Photo: Oda Hveem
Centre for Molecular Medicine Norway (NCMM), University of Oslo, is one of 19 partners in the four-year project. The project aims to build capabilities and deliver innovative scientific tools to support the long-term sustainability of EATRIS as one of Europe’s key research infrastructures.
Title of proposal: EATRIS-Plus – Consolidating the capacities of EATRIS-ERIC for personalised medicine
Start date: 2020 (precise date to be confirmed)
Duration: 48 months
EATRIS-plus will ensure sustainability of EATRIS
In the first five years of operations, EATRIS has shown strong proof of concept of the value and utility of the services portfolio, with users including academia, SMEs, large pharma, biotech and research funding organisations. The overarching aim of EATRIS-Plus is to support the long-term sustainability (LTS) of EATRIS by delivering innovative scientific tools to the research community, strengthening the infrastructure’s financial model and reinforcing EATRIS leadership in the European Research Area (ERA), particularly in the field of Personalised Medicine (PM) research and development.
Specific objectives include: (i) to consolidate EATRIS capacities in the field of PM to better serve academia and industry and augment the number of EATRIS Innovation Hubs with large pharma; (ii) to further strengthen the LTS of the EATRIS financial model; (iii) to drive patient empowerment through active involvement in the infrastructure’s operations; and (iv) to expand strategic partnerships with research infrastructures and other relevant stakeholders. The proposal relies on a scientific and technological programme combined with capacity-building activities across 16 EU countries, with the support of two umbrella organisations representing patient organisations and SMEs.
Pooling of EATRIS’ omics technologies will better address challenges of personalised medicine
EATRIS-Plus will help pooling and exploiting the translational academic capacities of the infrastructure in omics technologies to enable researchers to better address the scientific and societal challenges of PM. Additionally, the coordination office and 13 existing national nodes of the infrastructure will participate in implementing joint outreach, training, industry engagement and international collaboration activities to further build national capacity, increase users’ trust and strengthen EATRIS and the ERA global scientific leadership.
Norway formally entered EATRIS as a full member in 2016. The EATRIS infrastructure plays an important role in the advancement of knowledge and technology in translational research and drug development and currently comprises over 80 leading academic institutions across 12 European countries.
NCMM coordinates the Norwegian participation in EATRIS. Learn more about EATRIS in Norway on the NCMM website.